Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma.

Autor: Tso FY; Nebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, NE, United States of America.; School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE, United States of America., Lidenge SJ; Nebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, NE, United States of America.; School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE, United States of America.; Ocean Road Cancer Institute, Dar es Salaam, Tanzania.; Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania., Poppe LK; Nebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, NE, United States of America.; School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE, United States of America., Peña PB; Nebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, NE, United States of America.; School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE, United States of America., Privatt SR; Nebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, NE, United States of America.; School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE, United States of America., Bennett SJ; Nebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, NE, United States of America.; School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE, United States of America., Ngowi JR; Ocean Road Cancer Institute, Dar es Salaam, Tanzania., Mwaiselage J; Ocean Road Cancer Institute, Dar es Salaam, Tanzania.; Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania., Belshan M; Nebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, NE, United States of America.; Department of Medical Microbiology & Immunology, Creighton University, Omaha, NE, United States of America., Siedlik JA; Department of Exercise Science and Pre-Health Professions, Creighton University, Omaha, NE, United States of America., Raine MA; Department of Medical Microbiology & Immunology, Creighton University, Omaha, NE, United States of America., Ochoa JB; Department of Surgery, Ochsner Medical Center, New Orleans, LA, United States of America., Garcia-Diaz J; Department of Internal Medicine Ochsner Medical Center, New Orleans, LA, United States of America., Nossaman B; Department of Internal Medicine Ochsner Medical Center, New Orleans, LA, United States of America., Buckner L; Department of Internal Medicine Ochsner Medical Center, New Orleans, LA, United States of America., Roberts WM; Department of Internal Medicine Ochsner Medical Center, New Orleans, LA, United States of America., Dean MJ; Louisiana State University Cancer Center, New Orleans, LA, United States of America., Ochoa AC; Louisiana State University Cancer Center, New Orleans, LA, United States of America.; Department of Pediatrics LSU Health, New Orleans, LA, United States of America., West JT; Nebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, NE, United States of America.; Department of Biochemistry, University of Nebraska-Lincoln, Lincoln, NE, United States of America., Wood C; Nebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, NE, United States of America.; School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE, United States of America.; Department of Biochemistry, University of Nebraska-Lincoln, Lincoln, NE, United States of America.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2021 Mar 04; Vol. 16 (3), pp. e0247640. Date of Electronic Publication: 2021 Mar 04 (Print Publication: 2021).
DOI: 10.1371/journal.pone.0247640
Abstrakt: Background: Neutralizing-antibody (nAb) is the major focus of most ongoing COVID-19 vaccine trials. However, nAb response against SARS-CoV-2, when present, decays rapidly. Given the myriad roles of antibodies in immune responses, it is possible that antibodies could also mediate protection against SARS-CoV-2 via effector mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), which we sought to explore here.
Methods: Plasma of 3 uninfected controls and 20 subjects exposed to, or recovering from, SARS-CoV-2 infection were collected from U.S. and sub-Saharan Africa. Immunofluorescence assay was used to detect the presence of SARS-CoV-2 specific IgG antibodies in the plasma samples. SARS-CoV-2 specific neutralizing capability of these plasmas was assessed with SARS-CoV-2 spike pseudotyped virus. ADCC activity was assessed with a calcein release assay.
Results: SARS-CoV-2 specific IgG antibodies were detected in all COVID-19 subjects studied. All but three COVID-19 subjects contained nAb at high potency (>80% neutralization). Plasma from 19/20 of COVID-19 subjects also demonstrated strong ADCC activity against SARS-CoV-2 spike glycoprotein, including two individuals without nAb against SARS-CoV-2.
Conclusion: Both neutralizing and non-neutralizing COVID-19 plasmas can mediate ADCC. Our findings argue that evaluation of potential vaccines against SARS-CoV-2 should include investigation of the magnitude and durability of ADCC, in addition to nAb.
Competing Interests: The authors have declared that no competing interests exist.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje